Philippe De Wals

Summary

Country: Canada

Publications

  1. doi Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Quebec, Canada
    JAMA 308:175-81. 2012
  2. doi How to compare the efficacy of conjugate vaccines to prevent acute otitis media?
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Pavillon de l Est, 2180 chemin Sainte Foy, Suite 1108, Quebec City, Canada G1K 7P4
    Vaccine 27:2877-83. 2009
  3. ncbi Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec, Canada
    Clin Infect Dis 40:1116-22. 2005
  4. ncbi Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine
    Philippe De Wals
    Quebec National Public Health Institute and Department of Preventive and Social Medicine, Laval University, Quebec City, Quebec
    JAMA 292:2491-4. 2004
  5. doi Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Pediatr Infect Dis J 27:963-8. 2008
  6. ncbi Trend in prevalence of neural tube defects in Quebec
    Philippe De Wals
    Departement de Medecine sociale et preventive, Universite Laval, Quebec, Canada
    Birth Defects Res A Clin Mol Teratol 67:919-23. 2003
  7. doi Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Clin Infect Dis 46:e75-7. 2008
  8. doi Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Pediatr Infect Dis J 28:e271-5. 2009
  9. ncbi Uptake of pneumococcal conjugate vaccine: methodological issues in measurement and impact of publicly funded programs
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC
    Can J Public Health 100:413-6. 2009
  10. ncbi Impact of folic acid food fortification on the birth prevalence of lipomyelomeningocele in Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada
    Birth Defects Res A Clin Mol Teratol 82:106-9. 2008

Collaborators

Detail Information

Publications58

  1. doi Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Quebec, Canada
    JAMA 308:175-81. 2012
    ..In fall 2009 in Quebec, Canada, an immunization campaign was launched against the 2009 influenza A(H1N1) pandemic strain, mostly using an AS03 adjuvant vaccine. By the end of the year, 57% of the 7.8 million residents had been vaccinated...
  2. doi How to compare the efficacy of conjugate vaccines to prevent acute otitis media?
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Pavillon de l Est, 2180 chemin Sainte Foy, Suite 1108, Quebec City, Canada G1K 7P4
    Vaccine 27:2877-83. 2009
    ..More studies on the current aetiology of AOM need to be performed to accurately predict the marginal benefit of a switch from PCV7-CRM(197) to the newly licensed PCV10-HiD-DiT or to the future PCV13-CRM(197)...
  3. ncbi Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec, Canada
    Clin Infect Dis 40:1116-22. 2005
    ....
  4. ncbi Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine
    Philippe De Wals
    Quebec National Public Health Institute and Department of Preventive and Social Medicine, Laval University, Quebec City, Quebec
    JAMA 292:2491-4. 2004
    ..Meningococcal polysaccharide vaccines are of limited effectiveness. New protein-polysaccharide conjugate vaccines have yet to be evaluated in field conditions...
  5. doi Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Pediatr Infect Dis J 27:963-8. 2008
    ....
  6. ncbi Trend in prevalence of neural tube defects in Quebec
    Philippe De Wals
    Departement de Medecine sociale et preventive, Universite Laval, Quebec, Canada
    Birth Defects Res A Clin Mol Teratol 67:919-23. 2003
    ..In 1998, fortification of flour with FA became mandatory. The objective of this study was to assess the impact of these measures on the prevalence of neural tube defects (NTDs) in the province of Quebec...
  7. doi Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Clin Infect Dis 46:e75-7. 2008
    ..In the cohort of 1.9 million individuals (age, 2 months to 20 years), observed postvaccination frequencies of GBS were not higher than expected...
  8. doi Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Pediatr Infect Dis J 28:e271-5. 2009
    ..In Canada, a 7-valent pneumococcal conjugate vaccine (PCV-7) was licensed in 2001, and free vaccination of children <5 years of age was offered in December 2004 in the province of Quebec...
  9. ncbi Uptake of pneumococcal conjugate vaccine: methodological issues in measurement and impact of publicly funded programs
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC
    Can J Public Health 100:413-6. 2009
    ..In Quebec, the pneumococcal conjugate vaccine was available on the private market as early as 2001 and has been included in the publicly funded immunization program since December 2004...
  10. ncbi Impact of folic acid food fortification on the birth prevalence of lipomyelomeningocele in Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada
    Birth Defects Res A Clin Mol Teratol 82:106-9. 2008
    ..This study was performed to assess the prevalence of LMMC in Canada in relation to the timing of food fortification...
  11. ncbi Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine
    Vladimir Gilca
    Institut National de Sante Publique du Quebec, Laval University, Quebec, Canada
    Hum Vaccin 6:212-8. 2010
    ..70-0.90). Three doses of RB administered at the age of 8-10 years induce a 10 years long-lasting immunity in virtually all vaccinees. The booster does not appear necessary on a 10 years perspective...
  12. doi Spina bifida before and after folic acid fortification in Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada
    Birth Defects Res A Clin Mol Teratol 82:622-6. 2008
    ..A multicentric study was carried out to assess the impact of this policy on the frequency of NTDs. The present analysis focused on spina bifida...
  13. pmc Burden of acute otitis media on Canadian families
    Eve Dube
    Quebec National Institute of Public Health, Quebec, QC
    Can Fam Physician 57:60-5. 2011
    ..To estimate the burden of acute otitis media (AOM) on Canadian families...
  14. doi Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine
    Vladimir Gilca
    Institut National de Sante Publique du Quebec, Universite Laval, Quebec, Canada
    Vaccine 31:448-51. 2013
    ..These results do not support the need of a booster for at least 15 years when vaccinating preadolescents with Engerix-B...
  15. doi Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later
    Vladimir Gilca
    Institut National de Sante Publique du Quebec, Laval University, Quebec, Canada
    Vaccine 27:6048-53. 2009
    ..The excellent anamnestic response observed after the booster dose demonstrates the persistence of immunity in virtually all young adults vaccinated at the age of 8-10 with three paediatric doses of Engerix-B...
  16. pmc Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection
    Marc Brisson
    Departement de Medecine sociale et preventive, Universite Laval, Quebec, Que
    CMAJ 177:464-8. 2007
    ..A vaccine against human papillomavirus (HPV) types 6, 11, 16 and 18 is now licensed for use in Canada and many other countries. We sought to estimate the number needed to vaccinate to prevent HPV-related diseases and death...
  17. ncbi Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country
    Bernard Duval
    Institut National de Sante Publique du Quebec, Quebec, Canada
    Pediatr Infect Dis J 24:213-8. 2005
    ..The long term effect of the booster dose in teenagers is unknown. We evaluated the immunogenicity of 2 pediatric hepatitis vaccines after primary vaccination and after a booster dose...
  18. ncbi Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada
    Genevieve Deceuninck
    Public Health Research Unit, Quebec University Hospital Research Centre, Quebec City, Canada
    Pediatr Infect Dis J 29:546-9. 2010
    ....
  19. ncbi Meningococcal C vaccines: the Canadian experience
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University and Quebec National Public Health Institute, Quebec, Canada
    Pediatr Infect Dis J 23:S280-4. 2004
    ....
  20. ncbi Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Pavillon de l Est, 2180 chemin Sainte Foy, Quebec, Que, Canada G1K 7P4
    Vaccine 22:1233-40. 2004
    ..If vaccine-induced immunity is waning rapidly, mass immunization or routine vaccination with booster dose(s) would be the best control options...
  21. doi New vaccines offering a larger spectrum of protection against acute otitis media: will parents be willing to have their children immunized?
    Eve Dube
    Quebec National Institute of Public Health, Quebec, Canada
    Int J Pediatr Otorhinolaryngol 73:987-91. 2009
    ..To examine parents' knowledge, attitudes and beliefs regarding acute otitis media (AOM) and parents' willingness to vaccinate their children with new vaccine offering larger spectrum of protection against AOM...
  22. doi Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec, Quebec, Canada
    Clin Ther 31:2152-69. 2009
    ..New health economic models are required to model the impact of PHiD-CV and compare its effectiveness with PCV-7...
  23. doi Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Pediatr Infect Dis J 30:566-9. 2011
    ..In 2002, 1 C-MCV dose was routinely offered to children 12 months of age...
  24. ncbi Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis
    Philippe De Wals
    Department of Preventive and Social Medicine, Laval University, Quebec City, Canada
    Vaccine 25:5433-40. 2007
    ..One dose of serogroup C meningococcal conjugate vaccine (MCV-C) at 12 months of age is the most common immunization schedule in Canada, but immunity may wane over time...
  25. ncbi Epidemiology of Guillain-Barré syndrome in the province of Quebec
    Genevieve Deceuninck
    Public Health Research Unit, Quebec University Hospital Centre, Quebec City, Canada
    Can J Neurol Sci 35:472-5. 2008
    ..In the province of Quebec, a population-based study of Guillain-Barré syndrome (GBS) was conducted at the time of a mass immunization campaign against meningococcal disease, in 2001...
  26. doi Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Vaccine 30:6416-20. 2012
    ..In the province of Quebec, Canada, PHiD-CV was introduced in the summer of 2009, replacing the 7-valent CRM197 vaccine (PCV-7). Transition to the new vaccine was recommended regardless of the number of PCV7 doses already administered...
  27. doi Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: methodological difficulties and imperfect solutions
    Philippe De Wals
    Department of Preventive and Social Medicine, Laval University, Quebec City, Canada
    Vaccine 27:3223-7. 2009
    ..In 2001, a mass immunization campaign was implemented in the province of Quebec, Canada, using a new serogroup C meningococcal conjugate vaccine (C-MCV)...
  28. doi Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada Quebec National Public Health Institute Institut national de Santé publique du Québec, Quebec City, Canada Quebec University Hospital Research Centre, Quebec City, Canada Electronic address
    Vaccine 32:1501-6. 2014
    ..The program was implemented in December 2004 with a catch-up for children <5 years. PCV-7 was first used and replaced, respectively, by PCV-10 in 2009 and by PCV-13 in 2011...
  29. pmc The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains
    Rodica Gilca
    Institut National de Sante Publique du Quebec, Quebec City, Quebec, Canada
    PLoS ONE 7:e50659. 2012
    ....
  30. ncbi Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation
    Philippe De Wals
    Faculty of Medicine, Laval University, and Quebec National Institute of Public Health, Canada
    Vaccine 24:3500-4. 2006
    ..Existing routine immunization schedules may not be optimal and should be designed to achieve the highest level of protection using the lowest number of doses...
  31. doi Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster
    Marc Brisson
    Departement de Medecine sociale et preventive, Universite Laval, Quebec, Canada
    Vaccine 28:3385-97. 2010
    ..Adding a 2-dose program may help guarantee high population-level effectiveness against varicella. However, the incremental benefit of a second dose is highly dependant on the effectiveness of the first dose and its impact on zoster...
  32. doi Biopsychosocial determinants of pregnancy length and fetal growth
    Jennifer St-Laurent
    Clinical Research Centre, Sherbrooke University Hospital Centre, Sherbrooke, Quebec, Canada
    Paediatr Perinat Epidemiol 22:240-8. 2008
    ..More studies are needed to identify the mechanisms by which adverse psychosocial factors are translated into adverse biological effects...
  33. ncbi Reduction in neural-tube defects after folic acid fortification in Canada
    Philippe De Wals
    Laval University, Quebec, Canada
    N Engl J Med 357:135-42. 2007
    ..We assessed changes in the prevalence of neural-tube defects in Canada before and after food fortification with folic acid was implemented...
  34. ncbi Pregnancy planning and folic acid supplement use: results from a survey in Quebec
    Pascale Morin
    Department of Community Health Sciences, University of Sherbrooke, Quebec, Canada
    Prev Med 35:143-9. 2002
    ..The aim of the study was to describe the association between pregnancy planning and vitamin supplement use...
  35. pmc Quality of life of children and their caregivers during an AOM episode: development and use of a telephone questionnaire
    Eve Dube
    Quebec National Institute of Public Health, d Estimauville, Quebec City, G1E 7G9, Canada
    Health Qual Life Outcomes 8:75. 2010
    ..The negative consequences of acute otitis media (AOM) on the quality of life (QOL) of children and their families need to be measured to assess benefits of preventive interventions...
  36. doi Optimizing the acceptability, effectiveness and costs of immunization programs: the Quebec experience
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, 1050 avenue de la Medecine, Quebec City, G1V 0A6, Canada
    Expert Rev Vaccines 10:55-62. 2011
    ..Vaccine uptake rate is high and, although a reduced number of doses are recommended for several vaccines, program effectiveness is highly satisfactory, as shown for hepatitis B, meningococcal and pneumococcal diseases...
  37. ncbi Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Que, Canada G1K 7P4
    Vaccine 21:3757-64. 2003
    ..Vaccination would result in net savings for society, if vaccine cost is less than 30 dollars per dose. Economic indicators of catch-up programs are less favorable than for routine infant immunization...
  38. pmc Trends of hepatitis A hospitalization and risk factors in Quebec, Canada, between 1990 and 2003
    Magalie Canuel
    Department of Social and Preventive Medicine, Laval University, Quebec, Canada
    BMC Infect Dis 7:31. 2007
    ..This study estimated the year and age specific hospitalization rates and distribution of risk factors for HA in Quebec, Canada, between 1990 and 2003...
  39. ncbi [Public health: the control of meningococcal disease in Quebec]
    Philippe De Wals
    Departement de Medecine sociale et preventive, Universite Laval, Pavillon de l Est, 2180, Chemin Sainte Foy, local 1110, Quebec, G1K 7P4 Canada
    Med Sci (Paris) 19:1011-5. 2003
    ..Clinical, epidemiological, economic and social studies were instrumental in the decision making for implementing these control programs...
  40. ncbi Measuring the intensity of pregnancy planning effort
    Pascale Morin
    CLSC de la Région Sherbrookoise, Quebec, Canada
    Paediatr Perinat Epidemiol 17:97-105. 2003
    ..In conclusion, this is the first questionnaire specifically designed to assess the intensity of pregnancy planning effort, a potentially important variable in epidemiological studies and clinical practice...
  41. ncbi Impact of a mass immunization campaign to control an outbreak of severe respiratory infections in Nunavik, northern Canada
    Abdoul Aziz Ndiaye
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Int J Circumpolar Health 65:297-304. 2006
    ....
  42. pmc Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010
    Jean Baptiste Le Meur
    Quebec Heart and Lung Institute Research Centre, Quebec City, Canada Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Int J Circumpolar Health 73:22691. 2014
    ..At the same time, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the routine immunization programme of infants, with catch-up for children up to 4 years of age...
  43. ncbi Influenza-like illness during pregnancy: results from a study in the eastern townships, Province of Quebec
    Jean de Dieu Tuyishime
    Clinical Research Centre, Sherbrooke University Hospital Centre, Sherbrooke, Quebec, Canada
    J Obstet Gynaecol Can 25:1020-5. 2003
    ..1) To assess the frequency of influenza and influenza-like illness (ILI) during pregnancy; (2) to explore the associated risk of adverse maternal and fetal outcomes...
  44. ncbi Immunization strategies for the control of serogroup C meningococcal disease in developed countries
    Philippe De Wals
    Laval University, and Quebec National Public Health Institute, Department of Social and Preventive Medicine, Pavillon de l Est, 2180 chemin Sainte Foy, Quebec G1K 7P4, Canada
    Expert Rev Vaccines 5:269-75. 2006
    ..A schedule consisting of a first dose around 1 year of age and a second dose around 12 years of age seems to be a very cost-effective option in most epidemiological scenarios...
  45. ncbi Effectiveness and cost comparison of two strategies for hepatitis B vaccination of schoolchildren
    Maryse Guay
    Direction de la sante publique, de la planification et de l évaluation, Régie régionale de la santé et des services sociaux de la Montérégie, Longueuil, QC
    Can J Public Health 94:64-7. 2003
    ..The aim of the current study was to compare the effectiveness and costs of school-based and clinic-based programs...
  46. ncbi Preadolescent non- and hyporesponders following three doses of hepatitis B vaccine need only one more dose
    Bernard Duval
    Institut National de Sante Publique du Quebec, 2400 rue d Estimauville, Que, G1E 7G9, Beauport, Canada
    Vaccine 20:3632-4. 2002
    ..Most healthy children, particularly if they are hyporesponders, will have reached the seroprotective level after one dose and will not need further injections...
  47. pmc The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine
    Adrienne Morrow
    Department of Social and Preventive Medicine, Laval University, Quebec City
    Can J Infect Dis Med Microbiol 18:121-7. 2007
    ..To evaluate the impact in Canada, it is essential to have an estimate of the burden of pneumococcal disease before routine use of the vaccine...
  48. ncbi The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia
    Marc Brisson
    Departement de Medecine sociale et preventive, Universite Laval, Quebec, Canada
    Hum Vaccin 4:238-45. 2008
    ..In conclusion, results suggest that vaccinating adults between the ages of 65 and 75 years is likely to be cost-effective and thus to be a judicious use of scarce health care resources...
  49. ncbi Validity of death and stillbirth certificates and hospital discharge summaries for the identification of neural tube defects in Quebec City
    Fassiatou Tairou
    Department of Social and Preventive Medicine, Laval University, Quebec City, Quebec, Canada
    Chronic Dis Can 27:120-4. 2006
    ....
  50. ncbi The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada
    Marc Brisson
    Departement de Medecine sociale et preventive, Universite Laval, Que, Canada
    Vaccine 25:5399-408. 2007
    ..Clinical trials have shown prophylactic human papillomavirus (HPV) vaccines to be effective against infection and disease. We examined whether HPV vaccination has the potential to be cost-effective...
  51. ncbi Reviews examining sugar-sweetened beverages and body weight: correlates of their quality and conclusions
    José Massougbodji
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada JM and PDW, and the Quebec Heart and Lung Institute Research Center, Quebec City, Canada YLB, RF, and PDW
    Am J Clin Nutr 99:1096-104. 2014
    ..The role of sugar-sweetened beverages (SSBs) in increasing obesity is of great scientific, clinical, and public health interest. Many reviews have been published on this topic in recent years with very different conclusions...
  52. pmc Relationship between regulatory status, quality of care, and three-year mortality in Canadian residential care facilities: a longitudinal study
    Gina Bravo
    Research Centre on Aging, Sherbrooke University Geriatric Institute, Quebec, Canada
    Health Serv Res 37:1181-96. 2002
    ..To compare the mortality rate in regulated and unregulated facilities, controlling for confounding variables, and investigate the effect of care quality on residents' length of survival...
  53. ncbi Pregnancy planning: a determinant of folic acid supplements use for the primary prevention of neural tube defects
    Pascale Morin
    CLSC de la Région Sherbrookoise SSPER Université de Sherbrooke, 50, Camirand Street, Sherbrooke, QC J1H 4J5
    Can J Public Health 93:259-63. 2002
    ..The objectives of this study were: to evaluate women's knowledge and beliefs with regard to folic acid; to estimate the frequency of vitamin supplement consumption; and to identify its determinants during the periconception period...
  54. ncbi Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis
    R Douglas Scott
    Division of Healthcare Quality Promotion Scott, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Am J Prev Med 23:98-105. 2002
    ..Surveillance of meningococcal disease among U.S. college students found an elevated rate of this disease among first-year students living in dormitories...
  55. ncbi Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec
    Philippe De Wals
    Department of Community Health Sciences, University of Sherbrooke, 3001 12th Avenue North, Sherbrooke, Quebec, Canada J1H 5N4
    Vaccine 20:2840-4. 2002
    ..These economic indices are less favorable than those for current routine immunization programs in Canada, but within the range of those for other common health interventions...
  56. ncbi A prospective evaluation of the Charlson Comorbidity Index for use in long-term care patients
    Gina Bravo
    Research Centre, Sherbrooke University Geriatric Institute, Sherbrooke, Canada
    J Am Geriatr Soc 50:740-5. 2002
    ..This study examined the prognostic value of the Charlson Comorbidity Index (CCI) in predicting 3-year mortality and functional decline in the LTC setting and compared its prognostic value to that of two data-derived comorbidity indices...
  57. pmc Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19)
    Dennis K S Law
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    J Clin Microbiol 44:2743-9. 2006
    ..The emergence of this clone of serogroup B meningococci occurred after a mass vaccination against serogroup C N. meningitidis, suggesting possible capsule replacement...
  58. ncbi Comments on the paper "the effectiveness of serogroup C meningococcal vaccine estimated from routine surveillance data" [P Rivest, R Allard, Vaccine 20 (2002) 2533-2536]
    Philippe De Wals
    Vaccine 21:2260-1; author reply 2262. 2003